Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Patients - Derived xenografts (PDX) are models of cancer in which tumors from patients with the above tissues or cells are injected into one or immunodeficient humanized mice. The PDX model mimics human tumor biology, allowing natural cancer progression and providing the most transformative research models to assess efficacy.
This report elaborates the market size, market characteristics, and market growth of the Patient Derived Xenograft or PDX Models industry, and breaks down according to the type, application, and consumption area of Patient Derived Xenograft or PDX Models. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Patient Derived Xenograft or PDX Models in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
In addition, chapters 8-12 consider the impact of COVID-19 on the regional economy.
Key players in the global Patient Derived Xenograft or PDX Models market covered in Chapter 13:
Crown Bioscience Inc.
Horizon Discovery Group Plc (Sage Labs Inc.)
Xenopat (Spain)
Xentech
Shanghai Lide Biotech Co. Ltd. (China)
The Jackson Laboratory
Champions Oncology Inc.
Bioduro (Us)
Charles River Laboratories International Inc.
Pharmatest Services Ltd.
Epo Berlin-Buch Gmbh
Oncodesign
Wuxi Apptec (Group of Subsidiaries Under Wuxi Pharmatec)
Urolead
Hera Biolabs
In Chapter 6, on the basis of types, the Patient Derived Xenograft or PDX Models market from 2015 to 2025 is primarily split into:
Mice Models
Rat Models
In Chapter 7, on the basis of applications, the Patient Derived Xenograft or PDX Models market from 2015 to 2025 covers:
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Academic & Research Institutions
Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5:
United States
Europe
China
Japan
India
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions are covered in Chapter 8, 9, 10, 11, 12:
North America (Covered in Chapter 8)
United States
Canada
Mexico
Europe (Covered in Chapter 9)
Germany
UK
France
Italy
Spain
Others
Asia-Pacific (Covered in Chapter 10)
China
Japan
India
South Korea
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 11)
Saudi Arabia
UAE
South Africa
Others
South America (Covered in Chapter 12)
Brazil
Others
2019
This report elaborates the market size, market characteristics, and market growth of the Patient Derived Xenograft or PDX Models industry, and breaks down according to the type, application, and consumption area of Patient Derived Xenograft or PDX Models. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Patient Derived Xenograft or PDX Models in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
In addition, chapters 8-12 consider the impact of COVID-19 on the regional economy.
Key players in the global Patient Derived Xenograft or PDX Models market covered in Chapter 13:
Crown Bioscience Inc.
Horizon Discovery Group Plc (Sage Labs Inc.)
Xenopat (Spain)
Xentech
Shanghai Lide Biotech Co. Ltd. (China)
The Jackson Laboratory
Champions Oncology Inc.
Bioduro (Us)
Charles River Laboratories International Inc.
Pharmatest Services Ltd.
Epo Berlin-Buch Gmbh
Oncodesign
Wuxi Apptec (Group of Subsidiaries Under Wuxi Pharmatec)
Urolead
Hera Biolabs
In Chapter 6, on the basis of types, the Patient Derived Xenograft or PDX Models market from 2015 to 2025 is primarily split into:
Mice Models
Rat Models
In Chapter 7, on the basis of applications, the Patient Derived Xenograft or PDX Models market from 2015 to 2025 covers:
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Academic & Research Institutions
Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5:
United States
Europe
China
Japan
India
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions are covered in Chapter 8, 9, 10, 11, 12:
North America (Covered in Chapter 8)
United States
Canada
Mexico
Europe (Covered in Chapter 9)
Germany
UK
France
Italy
Spain
Others
Asia-Pacific (Covered in Chapter 10)
China
Japan
India
South Korea
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 11)
Saudi Arabia
UAE
South Africa
Others
South America (Covered in Chapter 12)
Brazil
Others
Years considered for this report:
Historical Years:
2015-2019Base Year:
2019Estimated Year:
2020Forecast Period:
2020-2025Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
